Founded in 2000, OKTO is passionately focused on unique, leading-edge surgical technologies that: (1) significantly improve the quality of life for patients; (2) elevate the performance and productivity of eye care professionals; and (3) lower costs to the healthcare provider.

OKTO currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for ocular surface/ophthalmic reconstructive surgeries.

OKTO has a well-established network of alliances for the development, manufacturing and distribution of innovative surgical technologies. The Company uses a variety of innovation methods and strategic collaborations to develop and deliver technologies offering solutions. Key assets:

• OKTO is led and directed by an uncompromising management team made up of industry leaders in sales, marketing, product development, operations and regulatory affairs.
  
• OKTO Surgical Sales includes over forty specialty-trained, independent U.S. surgical sales reps.
  
• In 2002, OKTO formally formed its OKTO Surgical Advisory Board, comprising of worldwide surgeon-leaders in ophthalmology.
  
• The Company has formed and currently maintains strategic alliances with Innovative Ophthalmic Products, Inc. (IOP, Inc.), Advanced Meditech International (AMI) and Anthrogenesis Corporation (Cedar Knolls, NJ).

OKTO Ophtho is a privately held California corporation.